Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 32% above its 2-year average of 75.64%, near the high end of its 2-year range (0.00%–100.00%).
13.05% above its 12-month average of 88.46%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 74.02%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
88.46%
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+13.05%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
+132.99%
vs the sector median at left
Market Cap
$994.91M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$989.06M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$990.92M
Gross Margin
97.19%
TTM Avg
61.28%
3Y Avg
80.64%
5Y Avg
87.09%
Market Cap
$997.09M
Gross Margin
79.71%
TTM Avg
80.13%
3Y Avg
81.57%
5Y Avg
-49.18%
Market Cap
$1.00B
Gross Margin
53.74%
TTM Avg
53.23%
3Y Avg
56.54%
5Y Avg
58.23%
Market Cap
$933.68M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $970.53M | 100.00% | 88.46% | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $994.91M | 0.00% | 0.00% | 0.00% | 16.67% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $989.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| MeiraGTx Holdings plc (MGTX)vs › | $990.92M | 97.19% | 61.28% | 80.64% | 87.09% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $996.93M | N/A | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $997.09M | 79.71% | 80.13% | 81.57% | -49.18% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.00B | 53.74% | 53.23% | 56.54% | 58.23% |
| CeriBell, Inc. (CBLL)vs › | $932.37M | 88.90% | 87.31% | 85.47% | 85.47% |
| MoonLake Immunotherapeutics (MLTX)vs › | $933.68M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immatics N.V. (IMTX)vs › | $1.01B | 100.00% | 100.00% | 100.00% | 64.23% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 74.02% |
| 2026-03-31 | 79.80% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 0.00% |
